CONTEXT: In vitro and animal studies have reported conflicting results regarding an independent role for FSH in the regulation of bone turnover. OBJECTIVE: Our objective was to test the hypothesis that suppressing serum FSH while holding serum gonadal steroid levels stable in the eugonadal range will affect biochemical markers of bone metabolism in healthy men. PARTICIPANTS, DESIGN, AND SETTING:Eugonadal men aged 20 to 50 years participated in this randomized controlled trial at a tertiary care academic teaching hospital. INTERVENTIONS: Participants received monthly GnRH analog injections to suppress FSH secretion plus daily topical testosterone gel in prespecified doses (intervention group). Controls received matching placebos (control group). Subjects in the intervention group were individually matched with subjects in the control group to ensure that the mean testosterone and estradiol levels (measured every 4 weeks during the 16-week study period) in the 2 groups were similar. MAIN OUTCOME MEASURES: Biochemical markers of bone resorption (serum N-terminal telopeptide and C-terminal telopeptide), bone formation (serum osteocalcin), and FSH were measured at baseline and after 16 weeks of treatment. RESULTS:Serum FSH declined by 2% in the control group and by 60% in the intervention group (P < .0001 for the between-group difference). Despite the substantial suppression of serum FSH in the intervention group, serum N-terminal telopeptide, C-terminal telopeptide, and osteocalcin did not change in the intervention group, nor were any between-group differences observed. CONCLUSION: When gonadal steroid levels are held constant, short-to midterm suppression of FSH does not affect bone turnover in men. FSH does not appear to be a significant regulator of bone metabolism in eugonadal men.
RCT Entities:
CONTEXT: In vitro and animal studies have reported conflicting results regarding an independent role for FSH in the regulation of bone turnover. OBJECTIVE: Our objective was to test the hypothesis that suppressing serum FSH while holding serum gonadal steroid levels stable in the eugonadal range will affect biochemical markers of bone metabolism in healthy men. PARTICIPANTS, DESIGN, AND SETTING: Eugonadal men aged 20 to 50 years participated in this randomized controlled trial at a tertiary care academic teaching hospital. INTERVENTIONS:Participants received monthly GnRH analog injections to suppress FSH secretion plus daily topical testosterone gel in prespecified doses (intervention group). Controls received matching placebos (control group). Subjects in the intervention group were individually matched with subjects in the control group to ensure that the mean testosterone and estradiol levels (measured every 4 weeks during the 16-week study period) in the 2 groups were similar. MAIN OUTCOME MEASURES: Biochemical markers of bone resorption (serum N-terminal telopeptide and C-terminal telopeptide), bone formation (serum osteocalcin), and FSH were measured at baseline and after 16 weeks of treatment. RESULTS: Serum FSH declined by 2% in the control group and by 60% in the intervention group (P < .0001 for the between-group difference). Despite the substantial suppression of serum FSH in the intervention group, serum N-terminal telopeptide, C-terminal telopeptide, and osteocalcin did not change in the intervention group, nor were any between-group differences observed. CONCLUSION: When gonadal steroid levels are held constant, short-to midterm suppression of FSH does not affect bone turnover in men. FSH does not appear to be a significant regulator of bone metabolism in eugonadal men.
Authors: Joel S Finkelstein; Hang Lee; Sherri-Ann M Burnett-Bowie; J Carl Pallais; Elaine W Yu; Lawrence F Borges; Brent F Jones; Christopher V Barry; Kendra E Wulczyn; Bijoy J Thomas; Benjamin Z Leder Journal: N Engl J Med Date: 2013-09-12 Impact factor: 91.245
Authors: Matthew T Drake; Louise K McCready; Kelley A Hoey; Elizabeth J Atkinson; Sundeep Khosla Journal: J Clin Endocrinol Metab Date: 2010-07-07 Impact factor: 5.958
Authors: M R Smith; F J McGovern; A L Zietman; M A Fallon; D L Hayden; D A Schoenfeld; P W Kantoff; J S Finkelstein Journal: N Engl J Med Date: 2001-09-27 Impact factor: 91.245
Authors: Margaret L Gourlay; Bonny L Specker; Chenxi Li; Catherine A Hammett-Stabler; Jordan B Renner; Janet E Rubin Journal: Bone Date: 2011-11-07 Impact factor: 4.398
Authors: Charles M Allan; Robert Kalak; Colin R Dunstan; Kirsten J McTavish; Hong Zhou; David J Handelsman; Markus J Seibel Journal: Proc Natl Acad Sci U S A Date: 2010-12-13 Impact factor: 11.205
Authors: U Omodei; G Mazziotti; G Donarini; M Gola; V Guella; F Pagani; G Bugari; T Porcelli; A Giustina Journal: J Clin Endocrinol Metab Date: 2012-10-23 Impact factor: 5.958
Authors: Ling-Ling Zhu; Harry Blair; Jay Cao; Tony Yuen; Rauf Latif; Lida Guo; Irina L Tourkova; Jianhua Li; Terry F Davies; Li Sun; Zhuan Bian; Clifford Rosen; Alberta Zallone; Maria I New; Mone Zaidi Journal: Proc Natl Acad Sci U S A Date: 2012-08-20 Impact factor: 11.205
Authors: Dirk Vanderschueren; Michaël R Laurent; Frank Claessens; Evelien Gielen; Marie K Lagerquist; Liesbeth Vandenput; Anna E Börjesson; Claes Ohlsson Journal: Endocr Rev Date: 2014-09-09 Impact factor: 19.871
Authors: Luisella Cianferotti; Francesco Bertoldo; Marco Carini; John A Kanis; Alberto Lapini; Nicola Longo; Giuseppe Martorana; Vincenzo Mirone; Jean-Yves Reginster; Rene Rizzoli; Maria Luisa Brandi Journal: Oncotarget Date: 2017-05-18
Authors: Karin C Wu; Susan K Ewing; Xiaojuan Li; Sigurður Sigurðsson; Vilmundur Guðnason; Deborah M Kado; Trisha F Hue; Gina N Woods; Annegreet G Veldhuis-Vlug; Eric Vittinghoff; Mone Zaidi; Clifford J Rosen; Thomas Lang; Tiffany Y Kim; Ann V Schwartz; Anne L Schafer Journal: J Clin Endocrinol Metab Date: 2021-09-27 Impact factor: 6.134
Authors: Edouard G Mills; Lisa Yang; Morten F Nielsen; Moustapha Kassem; Waljit S Dhillo; Alexander N Comninos Journal: Endocr Rev Date: 2021-11-16 Impact factor: 19.871